Clinical Trial Update: Study of CC-5013 to Evaluate Safety, Pharmacokinetics and Effectiveness for Japanese Patients With Symptomatic Anemia Associated With Myelodysplastic Syndrome With a Del(5)(q31-33) Abnormality. [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating CC-5013 (lenalidomide) in Japanese patients with symptomatic anemia due to myelodysplastic syndrome with del(5)(q31-33) abnormality; co…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• CC-5013 (lenalidomide)

Snippet

Sponsor: Celgene | Conditions: Myelodysplastic Syndromes | Phase 2 | Status: COMPLETED | Results posted: 2013-12-17